middle.news
Racura moves RC220 leukaemia trial towards first patient
8:51am on Wednesday 18th of November, 2026 AEDT
•
Biotechnology
Read Story
Racura moves RC220 leukaemia trial towards first patient
8:51am on Wednesday 18th of November, 2026 AEDT
Key Points
Sheba Medical Center ethics approval for the EMILI Phase 2b/3 AML trial
Phase 2b to enrol up to 68 patients and is funded from existing cash
Site activation is targeted by the end of 2026, with first patient treatment expected in Q1 2027
Phase 3 progression depends on results, funding and regulatory consultation
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Racura Oncology (ASX:RAC)
OPEN ARTICLE